Clinical trial
A Phase II Trial Of Adjuvant Chemoradiation Following Pancreatic Resection For Adenocarcinomas Of The Pancreas Using 3-D Conformal Radiation With Cisplatin, 5FU, And Alpha-Interferon As Radiosensitizing Agents Followed By Gemcitabine
NCT00660270 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial Of Adjuvant Chemoradiation Following Pancreatic Resection For Adenocarcinomas Of The Pancreas Using 3-D Conformal Radiation With Cisplatin, 5FU, And Alpha-Interferon As Radiosensitizing Agents Followed By Gemcitabine
- Lead sponsor
- Washington University School of Medicine
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2002
- Completion date
- February 28, 2009
- Enrollment
- 53 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
pancreatic cancer